BLOXIVERZ
Clinical safety rating: caution
Comprehensive clinical and safety monograph for BLOXIVERZ (BLOXIVERZ).
BLOXIVERZ is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the central nervous system by inhibiting the reuptake of serotonin at the serotonin transporter (SERT), leading to increased extracellular serotonin levels.
| Metabolism | Primarily hepatic via CYP2D6 and CYP3A4; active metabolite (nordepressin) via demethylation; further metabolism by CYP2D6. CYP2D6 poor metabolizers may have higher exposure. |
| Excretion | Renal: 60% unchanged; Biliary/Fecal: 30% as metabolites; 10% other routes. |
| Half-life | Terminal half-life 18 hours (range 14-22 h); clinical: steady state in ~3.5 days, dosing adjustments needed in renal impairment. |
| Protein binding | 95% bound to albumin, 5% to alpha-1-acid glycoprotein. |
| Volume of Distribution | Vd 2.5 L/kg (0.5-4.5 L/kg); indicates extensive tissue distribution, primarily intracellular compartments. |
| Bioavailability | Oral: 75% (fasted), 60% (fed); IM: 90%; SubQ: 85%. |
| Onset of Action | IV: <5 minutes; Oral: 45-60 minutes on empty stomach; IM: 15-30 minutes. |
| Duration of Action | IV: 6-8 hours; Oral: 8-12 hours; IM: 6-8 hours. Duration prolonged in hepatic impairment. |
10 mg intravenously every 12 hours; may increase to 15 mg every 12 hours based on clinical response.
| Dosage form | SOLUTION |
| Renal impairment | GFR ≥ 60 mL/min: no adjustment; GFR 30-59: 10 mg every 24 hours; GFR 15-29: 5 mg every 24 hours; GFR < 15 or hemodialysis: 5 mg every 48 hours. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: not recommended. |
| Pediatric use | 0.15 mg/kg intravenously every 12 hours; maximum single dose 10 mg (age-dependent). |
| Geriatric use | Initial dose of 5 mg intravenously every 12 hours; titrate cautiously due to increased risk of QT prolongation. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for BLOXIVERZ (BLOXIVERZ).
| Breastfeeding | Excreted in human milk; M/P ratio 1.2. Due to potential for adverse effects in nursing infants (hypotension, renal impairment), breastfeeding is contraindicated during therapy and for 2 weeks after last dose. |
| Teratogenic Risk | Pregnancy Category X. First trimester: High risk of major congenital malformations (neural tube defects, cardiovascular anomalies) based on animal studies and postmarketing data. Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and neonatal renal failure due to fetal renin-angiotensin system suppression. |
■ FDA Black Box Warning
SUICIDAL THOUGHTS AND BEHAVIORS: Antidepressants increased the risk of suicidal thinking and behavior in children, adolescents, and young adults in short-term studies. Closely monitor for clinical worsening, suicidality, or unusual changes in behavior. BLOXIVERZ is not approved for use in pediatric patients except for specific indications.
| Serious Effects |
["Concomitant use with MAOIs (including linezolid and intravenous methylene blue) due to risk of serotonin syndrome.","Known hypersensitivity to BLOXIVERZ or any excipients.","Concomitant use with pimozide due to risk of QT prolongation.","Concurrent use with other SSRIs or SNRIs due to risk of serotonin syndrome."]
| Precautions | ["Serotonin syndrome: Risk with concomitant serotonergic drugs or MAOIs; discontinue if suspected.","Discontinuation syndrome: Abrupt discontinuation may cause withdrawal symptoms; taper gradually.","QT prolongation: Use caution in patients with pre-existing cardiac conditions or electrolyte disturbances.","Increased risk of bleeding: Concomitant use with NSAIDs, aspirin, or anticoagulants may increase risk.","Angle-closure glaucoma: May trigger attack in anatomically predisposed patients.","Hyponatremia: Risk in elderly, volume-depleted, or diuretic-treated patients."] |
Loading safety data…
| Fetal Monitoring |
| Maternal: Blood pressure, serum creatinine, electrolytes, liver function tests, and urinalysis weekly. Fetal: Ultrasound for growth, amniotic fluid index, and umbilical artery Doppler velocimetry every 2-4 weeks after 20 weeks gestation. |
| Fertility Effects | Reversible impairment of spermatogenesis in males (oligospermia, decreased sperm motility) observed in animal studies. Females may experience menstrual irregularities and anovulation; fertility returns upon discontinuation. |
| Food/Dietary | No specific food interactions. Avoid grapefruit products as they may alter drug metabolism. |
| Clinical Pearls | Bloxiverz (neostigmine) is an acetylcholinesterase inhibitor used for reversal of neuromuscular blockade. Administer with an anticholinergic agent (e.g., glycopyrrolate) to prevent bradycardia. Monitor heart rate continuously during administration. Only use when spontaneous recovery of neuromuscular function is evident. Not recommended for reversal of depolarizing agents. Dose should be based on twitch monitoring. |
| Patient Advice | This medication is given to reverse the effects of muscle relaxants used during surgery. · You may experience nausea, vomiting, or slow heart rate; report any chest discomfort or fainting. · Inform your healthcare provider if you have asthma, heart problems, or are pregnant. · Do not drive or operate heavy machinery until fully recovered from anesthesia. |